Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials Full Text
Translational Lung Cancer Research,  Review Article

Petrelli F. et al .– In advanced non–small cell lung cancer (NSCLC), the increasing number of active compounds available in second line settings makes overall survival (OS) with maintenance treatment a not frequently observed endpoint. In this study a literature review was conducted to examine whether post–progression survival (PPS) correlates with OS in maintenance trials. This is the first study that has explored the correlation of median OS with PFS and PPS in trials exploring maintenance therapy with both chemotherapy and molecular–targeted agents. The results indicate that, especially for trials including anti–EGFR TKIs, PPS is highly associated with OS (r=1). This correlation is strong even for chemotherapy arms (r=0.77). There is a weaker correlation between OS and PFS (r=0.37) and in particular, no correlation in chemotherapy trials (r=–0.06). Summarising all studies, however, PFS is a surrogate endpoint of survival for these trials exploring maintenance agents, and it represents a practical and reliable endpoint of activity.In relation to the strong effect of PPS on OS, PFS could be considered an appropriate endpoint for maintenance trials. However, a precise assessment of the disease course with a preplanned second–line therapy or an adjustment for treatments prescribed beyond progression is crucial.

Methods

  • In the present review, the median OS of modern (chemotherapy or molecular–targeted agents), phase III, and maintenance trials for patients with NSCLC not–progressing after 4–6 cycles of platinum–based therapy were divided into PFS and PPS.
  • The correlation of each of them with OS was then assessed through a regression analysis.
  • Evaluation of the PFS surrogacy of the OS was also performed.

Results

  • Ten trials with 11 arms were identified.
  • Overall, a stronger correlation was observed between OS and PPS [Spearman rank correlation coefficient (r) =0.75] than OS and PFS time (r=0.37).
  • The correlation of differences in median PFS (?PFS) and median OS (?OS) is 0.64 (P=0.0326).
  • The slope of the regression line is 0.76, indicating that a maintenance therapy producing a one–month gain in PFS will yield an estimated three weeks prolongation in OS.

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

1 Study: How red wine prevents cancer University of Colorado Health News, December 5, 2014

2 Toughest breast cancer may have met its match Johns Hopkins Medicine, December 11, 2014

3 New device may ease mammography discomfort Radiological Society of North America News, December 1, 2014

4 The dirty side of soap UC San Diego Health System, November 20, 2014

5 Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial The Lancet, December 11, 2014    Evidence Based Medicine    Clinical Article

6 Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: The Cancer-DACUS Study Journal of Clinical Oncology, October 10, 2014    Clinical Article

7 Every step you take: STING pathway key to tumor immunity The University of Chicago Medical Center News, November 24, 2014

8 Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial The Lancet Oncology, December 12, 2014    Clinical Article
Exclusive Author Commentary

9 Risk of second non-breast cancer after radiotherapy for breast cancer: A systematic review and meta-analysis of 762,468 patients Radiotherapy & Oncology, December 1, 2014    Evidence Based Medicine    Review Article

10 Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial The Lancet, December 22, 2014    Evidence Based Medicine    Clinical Article

11 Impact of the U.S. preventive services task force recommendations against PSA screening on prostate biopsy and cancer detection rates The Journal of Urology, December 10, 2014    Clinical Article

12 Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor–positive breast cancer: A trial of the Eastern Cooperative Oncology Group Journal of Clinical Oncology, November 26, 2014    Clinical Article

13 Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial The Lancet Oncology, October 30, 2014    Clinical Article

14 Serum copper is a simple but valuable prognostic marker in B-cell chronic lymphocytic leukemia International Journal of Hematology, October 24, 2014    Clinical Article

15 Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer Clinical Cancer Research, December 3, 2014    Clinical Article

16 Castration-resistant prostate cancer: AUA guideline amendment The Journal of Urology, November 24, 2014    Clinical Guideline

17 Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: A Dutch Colorectal Cancer Group (DCCG) randomised phase III trial Annals of Oncology, December 9, 2014    Clinical Article

18 Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology Clinical Practice Guideline endorsement Journal of Clinical Oncology, November 7, 2014    Clinical Guideline

19 Young patients with non–germinal center B-cell–like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: Analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B Journal of Clinical Oncology, November 18, 2014    Clinical Article

20 Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline based chemotherapy in HER2-positive breast cancer: Results of the randomised phase II EORTC 10054 study Annals of Oncology, December 8, 2014    Clinical Article

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Make smarter career moves with less time.

Sign up for our free job placement service today and have a dedicated career consultant help locate the right physician job for you!
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List